Search

531 Result(s)
Sort by

commitments to sustainable development

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Nurjanahs Story

Nurjanahs Story

Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
FOYA_Shanghai

FOYA_Shanghai

Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
CARMELINA-elderly-analysis

CARMELINA-elderly-analysis

CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Embracing diversity in clinical trials

Embracing diversity in clinical trials

At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
GioTag Final Data

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
FDA approval NexGard PLUS for dogs

FDA approval NexGard PLUS for dogs

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Spotlight on GPP

Spotlight on GPP

Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Our goal of transforming the treatment of neuroendocrine carcinomas

Our goal of transforming the treatment of neuroendocrine carcinomas

Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).